螺內酯 / 安達通
Spironolactone
共 4 個適應症評級
白話說:證據中等,有一定的支持。
證據分數 75 分(滿分 100) · 發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」 - US FDA 態度:支持
展開原文引用
「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」 - EU EFSA 態度:支持
展開原文引用
「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面
白話說:證據中等,有一定的支持。
證據分數 72 分(滿分 100) · 發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」 - US FDA 態度:支持
展開原文引用
「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」 - EU EFSA 態度:支持
展開原文引用
「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面
白話說:有初步證據,但研究規模還小,別當成定論。
證據分數 68 分(滿分 100) · 發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」 - US FDA 態度:支持
展開原文引用
「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」 - EU EFSA 態度:支持
展開原文引用
「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面
白話說:有初步證據,但研究規模還小,別當成定論。
證據分數 57 分(滿分 100) · 發布狀態:可參考,但附帶但書
- 第三方營養資料庫(國際)
展開原文引用
「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」 - US FDA 態度:支持
展開原文引用
「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」 - EU EFSA 態度:支持
展開原文引用
「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」
評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面